Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

194.81 -6.37 (-3.17%)
Streaming Delayed Price Updated: 2:37 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 980,602
Open 199.83
Bid (Size) 194.73 (300)
Ask (Size) 195.07 (300)
Prev. Close 201.18
Today's Range 192.41 - 201.00
52wk Range 110.03 - 202.41
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗
Via Stocktwits
News headline image
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share... 
Via StockStory

Performance

YTD
+9.6%
+9.6%
1 Month
+3.8%
+3.8%
3 Month
+24.7%
+24.7%
6 Month
+52.2%
+52.2%
1 Year
+36.7%
+36.7%

More News

Read More
News headline image
Why Biogen Stock Surged Almost 9% Higher on Friday ↗
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Via MarketMinute
Topics Intellectual Property
News headline image
Biogen (BIIB) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
Via StockStory
News headline image
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗
Via MarketBeat
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Via StockStory
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The Great Decoupling: How the AI Monetization Era Reshaped the Nasdaq in 2025
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Biogen Inc. (NASDAQ:BIIB) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
Via StockStory
Topics Artificial Intelligence Economy
News headline image
$7 Trillion "Witching Hour": Unprecedented Derivatives Expiration Sparks Volatility on Wall Street
Via MarketMinute
Topics Derivatives Economy Regulatory Compliance

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 194.81
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 02/09/26 02:37 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 28.60B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 29B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.